medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2011, Number 3

<< Back Next >>

Rev Invest Clin 2011; 63 (3)

F18-FDG-PET/CT in the evaluation of patients with suspected recurrent or persistent locally advanced cervical carcinoma

Cetina L, Serrano A, Cantú-de-León D, Pérez-Montiel D, Estrada E, Coronel J, Hernández-Lucio M, Dueñas-González A

Language: English
References: 39
Page: 227-235
PDF size: 100.27 Kb.


ABSTRACT

Background. Cervical cancer (CC) represents the second most common neoplasm and the third cause of death by cancer among women. Recurrent or persistent disease depends on the clinical stage, but can be as high as 70%. Positron emission tomography/computed tomography (PET/CT) is an image study that can detect increased glucose uptake in tumor tissues. Material and methods. PET/CT was performed in patients with confirmed CC, who had been previously treated, who developed suspected symptoms of recurrence or persistent disease with or without evidence of disease on a CT scan. Sensitivity, specificity, predictive values from PET/CT, and CT scan were evaluated. Results. Sixteen patients with a mean age of 47.2 years were included in the study from April 2007 to June 2008. Thirteen patients (81.2%) were symptomatic. PET/CT was positive in 14/16 (85.7%), of these, 12 True positive (TP) and two, False positive (FP); meanwhile another two cases were True negative (TN) (12.5%). Cervix, retroperitoneal, iliac, obturator, and mediastinal lymph nodes were the most common anatomic sites detected by PET/CT. Mean number of anatomic sites with high Fluorodeoxy- D-glucose (FDG) uptake was two sites (range 1-7 sites). PET/CT and CT scan had 100 and 91.7% sensitivity, respectively. Specificity for both was 50%. Positive predictive value (PPV) was 85.4 and 84.6%, respectively. Negative predictive value (NPV) was 100 and 66%, respectively, and accuracy was 88 vs. 81%, respectively. Conclusions. PET/CT has the capability for detecting recurrent or persistent cervical cancer; it detects increased metabolic activity mainly in primary site or lymph nodes. Further PET/CT evaluation is required to confirm the real impact of this study on the early detection of CC recurrence.


REFERENCES

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57(1): 43-66.

  2. International Agency for Research on Cancer. Globocan 2002. Available from: www-dep iarc.fr/

  3. Registro Histopatológico de Neoplasias Malignas. Compendio de mortalidad/morbilidad 2003. Secretaría de Salud (SSa). México. Disponible en: www.dgepi.salud.gob.mx/diveent/DIVEENT- INDEX.htm

  4. Jeong YY, Kang HK, Chung TW, Seo JJ, Park JG. Uterine cervical carcinoma after therapy: CT and MR imaging findings. Radiographics 2003; 23: 969-80.

  5. Kesic V. Management of cervical cancer. Eur J Surg Oncol 2006; 32: 832-7.

  6. Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, et al. Carcinoma of the cervix uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 (Suppl. 1): S43-S103.

  7. 7 . National Comprehensive Cancer Network. Cervical Cancer. Practice Guidelines in Oncology v.1.2009. Available from: www.nccn.org/professionals/physician_gls/PDF/ cervical/pdf

  8. Park DH, Kim KH, Park SY, Lee BH, Choi CW, Chin SY. Diagnosis of recurrent uterine cervical cancer: computed tomography versus positron emission tomography. Korean J Radiol 2000; 1: 51-5.

  9. Magné N, Chargari C, Vicenzi L, Gillon N, Messai T, Magné J, et al. New trends in the evaluation and treatment of cervical cancer: the role of FDG-PET. Cancer Treat Rev 2008; 34: 671-81.

  10. Lai CH, Yen TC, Chang TC. Positron emission tomography imaging for gynecologic malignancy. Curr Opin Obstet Gynecol 2007; 19: 37-41.

  11. Bomanji JB, Costa DC, Eli PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol 2001; 3: 157-64.

  12. Jerusalem G, Hustinx R, Beguin Y, Fillet G. PET scan imaging in oncology. Eur J Cancer 2003; 39: 1525-34.

  13. Yen TC, See LC, Lai CH, Yah-Huei CW, Ng KK, Ma SY, et al. 18F-FDG uptake in the squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med 2004; 45: 22-9.

  14. Chung HH, Kim SK, Kim TH, Lee S, Kang KW, Kim JY, Park SY. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine-cervical cancer: from diagnosis to prognosis. Gynecol Oncol 2006; 103: 165-70.

  15. Sakurai H, Suzuki Y, Nonaka T, Ishikawa H, Shioya M, Kiyohara H, et al. FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy-tumor volume and FDG uptake value. Gynecol Oncol 2006; 100: 601-7.

  16. Unger JB, Ivy JJ, Connor P, Charrier A, Ramaswamy RR, Ampil FL, Monsour RP. Detection of recurrent cervical cancer by whole-body FDG-PET scan in asymptomatic and symptomatic women. Gynecol Oncol 2004; 94: 212-6.

  17. Havrilesky LJ, Wong TZ, Álvarez-Secord A, Berchuk A, Clarke- Pearson DL, Jones EL. The role of PET scanning in the detection of recurrent cervical cancer. Gynecol Oncol 2003; 90: 186-90.

  18. Ryu SY, Kim MH, Choi SC, Choi CW, Lee KH. Detection of early recurrence with 18F-FDG PET in patients with cervical cancer. J Nucl Med 2003; 44: 347-52.

  19. Yildirim Y, Sehirali S, Avci ME, Yilmaz C, Ertopcu K, Tinar S, et al. Integrated PET/CT for the evaluation of para-aortic nodal metastasis in locally advanced cervical cancer patients with negative conventional CT findings. Gynecol Oncol 2008; 108: 154-9.

  20. Sironi S, Buda A, Picchio M, Perego P, Moreni R, Pellegrino A, et al. Lymph-node metastasis in patients with clinical earlystage cervical cancer: detection with integrated FDG-PET/CT. Radiology 2006; 238: 272-9.

  21. Chung HH, Jo H, Kang WJ, Kim JW, Park NH, Song YS, et al. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. Gynecol Oncol 2007; 104: 529-34.

  22. Hricak H, Yu KK. Radiology in invasive cervical cancer. Am J Roentgenol 1996; 167: 1101-8.

  23. Amit A, Beck D, Lowenstein L, Lavie O, Bar Shalom R, Kedar Z, Israel O. The role of hybrid PET/CT in the evaluation of patients with cervical cancer. Gynecol Oncol 2006; 100: 65-9.

  24. Sugawara Y, Eisbruch A, Kosuda S, Recker BE, Kison PV, Wahl RL. Evaluation of FDG PET in patients with cervical cancer. J Nucl Med 1999; 40: 1125-31.

  25. Kitajima K, Murakami K, Yamasaki E, Domeki Y, Kaji Y, Sugimura K. Performance of FDG-PET/CT for diagnosis of recurrent uterine cervical cancer. Eur Radiol 2008; 18: 2040-7.

  26. Kitajima K, Murakami K, Yamasaki E, Domeki Y, Kaji Y, Morita S, et al. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis in recurrent uterine cancer: comparison with PET and enhanced CT. Eur J Nucl Med Mol Imag 2009; 36: 362-72.

  27. Wong TZ, Jones EL, Coleman RE. Positron emission tomography with 2-deoxy-2[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer. Mol Imag Biol 2004; 6: 55-62.

  28. Chang TC, Law KS, Hong JH, Lai CH, Ng KK, Hsueh S, et al. Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during followup for patients with cervical malignancies: a phase II study. Cancer 2004; 101: 164-71.

  29. Sun SS, Chen TC, Yen RF, Shen YY, Changlai SP, Kao A. Value of whole body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer. Anticancer Res 2001; 21: 2957-61.

  30. Yen TC, See LC, Chang TC, Huang KG, Ng KK, Tang SG, et al. Defining the priority of using 18F-FDG PET for recurrent cervical cancer. J Nucl Med 2004; 45: 1632-9.

  31. Yen TC, Lai CH, Ma SY, Huang KG, Huang HJ, Hong JH, et al. Comparative benefits and limitations of 18F-FDG-PET and CT-MRI in documented or suspected recurrent cervical cancer. Eur J Nucl Med Mol Imaging 2006; 33: 1399-407.

  32. Lai CH, Huang KG, See LC, Yen TZ, Tsai CS, Chang TC, et al. Restaging recurrent cervical carcinoma with dual-phase [18F]- Fluoro-2-deoxy-D-glucose positron emission tomography. Cancer 2004; 100: 544-52.

  33. Lin CT, Yen TC, Chang TC, Ng KK, Tsai CS, Ho KC, Lai CH. Role of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in re-recurrent cervical cancer. Int J Gynecol Cancer 2006; 16: 1994-2003.

  34. Husain A, Akhurst T, Larson S, Alektiar K, Barakat RR, Chi DS. A prospective study of the accuracy of 18-F-fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration. Gynecol Oncol 2007; 106: 177-80.

  35. Bodurka-Bavers D, Morris M, Eifel PJ, Levenback C, Bevers MW, Lucas KR, Wharton JT. Post-therapy surveillance of women with cervical cancer: an outcome analysis. Gynecol Oncol 2000; 78: 187-93.

  36. Zola P, Fuso L, Mazzola S, Piovano E, Perotto S, Gadducci A, et al. Could follow-up different modalities play a role in asymptomatic cervical cancer relapses diagnosis? An Italian multicenter retrospective analysis. Gynecol Oncol 2007; 107(Suppl.): S150-S154.

  37. Soisson AP, Geszler G, Soper JT, Berchuk A, Clarke-Pearson DL. A comparison of symptomatology, physical examination, and vaginal cytology in the detection of recurrent carcinoma after hysterectomy. Obstet Gynecol 1990; 76: 106-9.

  38. Brooks RA, Rader JS, Dehdashti F, Mutch DG, Powell MA, Thaker PH, et al. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol 2009; 112: 104-9.

  39. Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [18F] flourodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 2004; 22: 2167-71.




2020     |     www.medigraphic.com